Dual acting antioxidant A1 adenosine receptor agonists

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Neuroscience

Background:

• Adenosine receptors play crucial roles in cardiovascular function.
• Developing selective A(1) adenosine receptor agonists is a therapeutic goal.
• Antioxidant moieties can offer protective benefits in cardiovascular disease.

Purpose of the Study:

• To synthesize and evaluate novel A(1) adenosine receptor agonists.
• To incorporate antioxidant properties into these agonists.
• To explore the potential cardioprotective effects of combined A(1) agonism and antioxidant activity.

Main Methods:

• Chemical synthesis of functionalized adenosine derivatives.
• Biological evaluation of receptor binding affinity and selectivity.
• Assessment of antioxidant properties of synthesized compounds.

Main Results:

• N(6)-(2,2,5,5-Tetramethylpyrrolidin-1-yloxyl-3-ylmethyl)adenosine (VCP28, 2e) demonstrated high affinity (K(i)=50nM) and selectivity (A(3)/A(1) >= 400) for A(1) adenosine receptors.
• N(6)-[4-[2-[1,1,3,3-Tetramethylisoindolin-2-yloxyl-5-amido]ethyl]phenyl]adenosine (VCP102, 5a) exhibited higher binding affinity (K(i)=7 nM) but lower selectivity (A(3)/A(1) approx. 3).
• All tested compounds showed weak binding to A(2A) and A(2B) receptors (K(i)>1 microM).

Conclusions:

• The synthesized compounds are potent and selective A(1) adenosine receptor agonists.
• The combination of A(1) agonist activity and antioxidant properties holds promise for cardioprotection.
• Further investigation into these compounds could lead to novel therapeutic strategies for cardiovascular conditions.